|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio of ASP7035 in Patients with Nocturia Associated with Norturnal Polyuria
100 Clinical Results associated with Tacurion Pharma, Inc.
0 Patents (Medical) associated with Tacurion Pharma, Inc.
100 Deals associated with Tacurion Pharma, Inc.
100 Translational Medicine associated with Tacurion Pharma, Inc.